A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Breast cancer; Colorectal cancer
- Focus Adverse reactions
- Sponsors Amgen
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 02 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 12 Apr 2018.
- 06 Feb 2018 Planned End Date changed from 25 Apr 2021 to 13 May 2021.